The latest report from Future Market Insights predicts a promising growth trajectory for the global atrophic vaginitis treatment market, which is anticipated to expand at a compound annual growth rate (CAGR) of 8% from 2023 to 2033. As the market gears up to hit a substantial valuation of US$ 6 billion by 2033, starting from US$ 2.78 billion in 2023, stakeholders are optimistic about the potential advances and broader adoption of effective treatments catering to increasing demand.
Atrophic vaginitis, a condition that primarily affects postmenopausal women, results in symptoms such as vaginal dryness, itching, and painful intercourse. A report by the National Institutes of Health highlights that around 50% of women experience vaginal discomfort after menopause, with 10-40% suffering from atrophic vaginitis. This reflects a significant patient pool that requires effective and sustained treatment options.
Get Sample Copy of Latest Reports: https://www.futuremarketinsights.com/reports/sample/rep-gb-16831
The market offers a range of therapies to address the symptoms of atrophic vaginitis. Among them, hormone replacement therapy (HRT) stands out as a highly effective approach. HRT works by supplementing the body with hormones to replace the estrogen no longer naturally produced, helping alleviate common symptoms associated with the condition.
Additionally, topical estrogen creams and vaginal moisturizers continue to be part of an essential treatment regimen, providing relief and improving the quality of life for millions of women worldwide.
This growth in the atrophic vaginitis treatment market is underpinned by an increasing awareness of the condition and more proactive healthcare behaviors among women, alongside advancements in treatment solutions. Healthcare providers and companies in the pharmaceutical sector are also contributing to the development of more effective and less invasive treatment options, further driving the market’s expansion.
As the market for atrophic vaginitis treatment grows, it opens up numerous opportunities for innovation and development, ensuring that women suffering from this condition have access to the best possible care.
Key Takeaways from the Market Study:
- The global Atrophic vaginitis treatment market is expected to grow with an 8% CAGR during 2023 to 2033.
- By therapy type, Estrogen based therapy are expected to hold 53% of the market share in 2023 for Atrophic vaginitis treatment market.
- North America is expected to possess 48% market share for Atrophic vaginitis treatment market in 2023.
- Europe Atrophic vaginitis treatment market size is expected to possess 43% market share in 2023.
“The atrophic vaginitis treatment market is revolutionizing women’s health by providing effective solutions to a common condition that affects millions of women worldwide. With the increasing prevalence of the condition, the market is expected to grow significantly in the coming years. Despite the challenges faced by the industry” states an FMI analyst
Request Methodology Now: https://www.futuremarketinsights.com/request-report-methodology/rep-gb-16831
Competitive Landscape:
Key players in the atrophic vaginitis treatment are Shionogi, Duchesnay, Hormos Medical, QuatRx Pharmaceuticals, Pantarhei Bioscience, Mithra Pharmaceuticals, AMAG Pharmaceuticals, Bayer HealthCare Pharmaceuticals Inc, Theramex, Endoceutics, Inc.
- Shionogi is a pharmaceutical company that has developed a treatment for atrophic vaginitis called Intrarosa (prasterone). Intrarosa is a vaginal insert that contains the hormone dehydroepiandrosterone (DHEA), which is converted into estrogen in the body.
- Bayer HealthCare Pharmaceuticals Inc, a key player in the atrophic vaginitis treatment market is focusing on developing treatments for the ailment by researching and investing in developing therapies.
Key Segments Profiled in the Atrophic Vaginitis Treatment Industry Survey:
Diagnosis:
- Pelvic exam
- Urine test
- Acid balance test
Treatment:
- Vaginal moisturizers
- Water-based lubricants
Therapy Type:
- Estrogen based drugs
- Non-estrogen based drugs
Distribution Channel:
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
Direct Purchase of this Report: https://www.futuremarketinsights.com/checkout/16831
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube